CN100425991C - 一种用于检测sars抗体的免疫微球及其制备方法和用途 - Google Patents
一种用于检测sars抗体的免疫微球及其制备方法和用途 Download PDFInfo
- Publication number
- CN100425991C CN100425991C CNB2004100701474A CN200410070147A CN100425991C CN 100425991 C CN100425991 C CN 100425991C CN B2004100701474 A CNB2004100701474 A CN B2004100701474A CN 200410070147 A CN200410070147 A CN 200410070147A CN 100425991 C CN100425991 C CN 100425991C
- Authority
- CN
- China
- Prior art keywords
- leu
- thr
- ser
- ala
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种用于检测SARS抗体的免疫微球,及其制备方法和用途。该免疫微球是以表面有羧基修饰的聚苯乙烯微球为内核,其表面的羧基通过多聚赖氨酸化学偶联了作为抗原的SARS冠状病毒S,N,M或E蛋白。该免疫微球可以作为检测试剂检测抗SARS抗体。本发明提供的用于检测SARS抗体的免疫微球与现有技术相比,其敏感性和特异性好,准确性高,避免了PCR诊断试剂盒的假阳性的缺点;整个检测过程快速;检测不需要任何仪器设备,经济实用,适合广大基层卫生防疫单位使用。
Description
技术领域
本发明涉及一种用于检测SARS抗体的免疫微球,及其制备方法和用途。
技术背景
SARS(严重急性呼吸综合症)冠状病毒是一种新发现的冠状病毒,其引起的这种新型疾病发病快,传播速度快,若不及时诊断治疗,病死率非常高。
目前在科研和临床上常用的检测方法是酶联免疫法(ELISA)。使用酶联免疫法(ELISA)检测抗体,即将抗原包被酶标板上,加小牛血清或脱脂奶封闭,再加待测血清后温育1小时,经反复冲洗后加酶标第二抗体,温育,再冲洗多次后加显色的底物。此法虽然敏感性和特异性很好,但是要完成全部试验需要2小时以上。
而使用免疫微球法检测抗体是一种简便、快速的方法,只需1分钟就可得到结果。该方法是将抗原偶联或交联到有机聚合物制备的微球上,制成免疫微球试剂来检测抗体。但是现有的免疫微球试剂的制备方法,无论是物理或是化学方法,得到的免疫微球均不是通过共价键结合的,因此免疫微球本身很不稳定,受温度和盐浓度影响很大,容易造成假阳性的实验误差。
发明内容
本发明的目的在于克服现有酶联免疫法不够简便、快速;而免疫微球法的免疫微球本身很不稳定,容易造成假阳性实验误差的缺陷,从而提供一种既可以快速、简便的检测,又很稳定的用于检测SARS抗体的免疫微球。
本发明的另一目的在于提供一种所述的用于检测SARS抗体的免疫微球的制备方法。
本发明的再一目的在于提供一种所述的用于检测SARS抗体的免疫微球的用途。
本发明的目的是通过如下的技术方案实现的:
本发明提供的用于检测SARS(严重急性呼吸综合症)抗体的免疫微球,其为以聚苯乙烯微球为内核,其表面的羧基通过多聚赖氨酸偶联了作为抗原的SARS冠状病毒S,N,M或E蛋白,所述的聚苯乙烯微球为表面直径为200~900纳米,其表面有羧基修饰。
本发明提供一种所述的用于检测SARS抗体的免疫微球的制备方法,是采用化学偶联法将SARS冠状病毒S,N,M或E蛋白作为抗原偶联到微球,包括如下的步骤:
1)将聚苯乙烯微球15~20mg/ml,用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤后,重悬于0.01~0.05M的pH4~5的磷酸缓冲液,然后加入2~4mg/ml的碳二亚胺,于室温反应完全后,离心,用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤,重悬于0.01~0.05M的pH 7.5~8.5的碳酸盐缓冲液;所述的聚苯乙烯微球直径为200~900纳米,其表面有羧基修饰;
2)向步骤1)得到的混合液中加入0.2~2.4mg/ml的多聚赖氨酸,于室温反应完全;用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤后,重悬于0.01~0.05M的pH4~5的磷酸缓冲液,然后加入2~4mg/ml的碳二亚胺,于室温反应完全;用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤,重悬于0.01~0.05M的pH 7.5~8.5的碳酸盐缓冲液;
3)向步骤2)得到的混合液中加入作为抗原的SARS冠状病毒S,N,M或E蛋白0.2~2.4mg/ml,于室温反应完全;用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤后,重悬于0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液;加入50~200微升0.25M乙酰胺,于室温反应完全后,离心分出固体;
4)重悬于1g/ml牛血清(BSA)和0.01~0.05M的pH 7.5~8.5的碳酸盐缓冲液,于室温反应完全后,离心分出固体,得到用于检测SARS抗体的免疫微球。
所述的SARS冠状病毒S蛋白的氨基酸序列为:
MetPheIlePheLeu LeuPheLeuThrLeu ThrSerGlySerAsp LeuAspArgCysThr
ThrPheAspAspVal GlnAlaProAsnTyr ThrGlnHisThrSer SerMetArgGlyVal
TyrTyrProAspGlu IlePheArgSerAsp ThrLeuTyrLeuThr GlnAspLeuPheLeu
ProPheTyrSerAsn ValThrGlyPheHis ThrIleAsnHisThr PheAspAsnProVal
IleProPheLysAsp GlyIleTyrPheAla AlaThrGluLysSer AsnValValArgGly
TrpValPheGlySer ThrMetAsnAsnLys SerGlnSerValIle IleIleAsnAsnSer
ThrAsnValValIle ArgAlaCysAsnPhe GluLeuCysAspAsn ProPhePheAlaVal
SerLysProMetGly ThrGlnThrHisThr MetIlePheAspAsn AlaPheAsnCysThr
PheGluTyrIleSer AspAlaPheSerLeu AspValSerGluLys SerGlyAsnPheLys
HisLeuArgGluPhe ValPheLysAsnLys AspGlyPheLeuTyr ValTyrLysGlyTyr
GlnProIleAspVal ValArgAspLeuPro SerGlyPheAsnThr LeuLysProIlePhe
LysLeuProLeuGly IleAsnIleThrAsn PheArgAlaIleLeu ThrAlaPheSerPro
AlaGlnAspThrTrp GlyThrSerAlaAla AlaTyrPheValGly TyrLeuLysProThr
ThrPheMetLeuLys TyrAspGluAsnGly ThrIleThrAspAla ValAspCysSerGln
AsnProLeuAlaGlu LeuLysCysSerVal LysSerPheGluIle AspLysGlyIleTyr
GlnThrSerAsnPhe ArgValValProSer GlyAspValValArg PheProAsnIleThr
AsnLeuCysProPhe GlyGluValPheAsn AlaThrLysPhePro SerValTyrAlaTrp
GluArgLysLysIle SerAsnCysValAla AspTyrSerValLeu TyrAsnSerThrPhe
PheSerThrPheLys CysTyrGlyValSer AlaThrLysLeuAsn AspLeuCysPheSer
AsnValTyrAlaAsp SerPheValValLys GlyAspAspValArg GlnIleAlaProGly
GlnThrGlyValIle AlaAspTyrAsnTyr LysLeuProAspAsp PheMetGlyCysVal
LeuAlaTrpAsnThr ArgAsnIleAspAla ThrSerThrGlyAsn TyrAsnTyrLysTyr
ArgTyrLeuArgHis GlyLysLeuArgPro PheGluArgAspIle SerAsnValProPhe
SerProAspGlyLys ProCysThrProPro AlaLeuAsnCysTyr TrpProLeuAsnAsp
TyrGlyPheTyrThr ThrThrGlyIleGly TyrGlnProTyrArg ValValValLeuSer
PheGluLeuLeuAsn AlaProAlaThrVal CysGlyProLysLeu SerThrAspLeuIle
LysAsnGlnCysVal AsnPheAsnPheAsn GlyLeuThrGlyThr GlyValLeuThrPro
SerSerLysArgPhe GlnProPheGlnGln PheGlyArgAspVal SerAspPheThrAsp
SerValArgAspPro LysThrSerGluIle LeuAspIleSerPro CysSerPheGlyGly
ValSerValIleThr ProGlyThrAsnAla SerSerGluValAla ValLeuTyrGlnAsp
ValAsnCysThrAsp ValSerThrAlaIle HisAlaAspGlnLeu ThrProAlaTrpArg
IleTyrSerThrGly AsnAsnValPheGln ThrGlnAlaGlyCys LeuIleGlyAlaGlu
HisValAspThrSer TyrGluCysAspIle ProIleGlyAlaGly IleCysAlaSerTyr
HisThrValSerLeu LeuArgSerThrSer GlnLysSerIleVal AlaTyrThrMetSer
LeuGlyAlaAspSer SerIleAlaTyrSer AsnAsnThrIleAla IleProThrAsnPhe
SerIleSerIleThr ThrGluValMetPro ValSerMetAlaLys ThrSerValAspCys
AsnMetTyrIleCys GlyAspSerThrGlu CysAlaAsnLeuLeu LeuGlnTyrGlySer
PheCysThrGlnLeu AsnArgAlaLeuSer GlyIleAlaAlaGlu GlnAspArgAsnThr
ArgGluValPheAla GlnValLysGlnMet TyrLysThrProThr LeuLysTyrPheGly
GlyPheAsnPheSer GlnIleLeuProAsp ProLeuLysProThr LysArgSerPheIle
GluAspLeuLeuPhe AsnLysValThrLeu AlaAspAlaGlyPhe MetLysGlnTyrGly
GluCysLeuGlyAsp IleAsnAlaArgAsp LeuIleCysAlaGln LysPheAsnGlyLeu
ThrValLeuProPro LeuLeuThrAspAsp MetIleAlaAlaTyr ThrAlaAlaLeuVal
SerGlyThrAlaThr AlaGlyTrpThrPhe GlyAlaGlyAlaAla LeuGlnIleProPhe
AlaMetGlnMetAla TyrArgPheAsnGly IleGlyValThrGln AsnValLeuTyrGlu
AsnGlnLysGlnIle AlaAsnGlnPheAsn LysAlaIleSerGln IleGlnGluSerLeu
ThrThrThrSerThr AlaLeuGlyLysLeu GlnAspValValAsn GlnAsnAlaGlnAla
LeuAsnThrLeuVal LysGlnLeuSerSer AsnPheGlyAlaIle SerSerValLeuAsn
AspIleLeuSerArg LeuAspLysValGlu AlaGluValGlnIle AspArgLeuIleThr
GlyArgLeuGlnSer LeuGlnThrTyrVal ThrGlnGlnLeuIle ArgAlaAlaGluIle
ArgAlaSerAlaAsn LeuAlaAlaThrLys MetSerGluCysVal LeuGlyGlnSerLys
ArgValAspPheCys GlyLysGlyTyrHis LeuMetSerPhePro GlnAlaAlaProHis
GlyValValPheLeu HisValThrTyrVal ProSerGlnGluArg AsnPheThrThrAla
ProAlaIleCysHis GluGlyLysAlaTyr PheProArgGluGly ValPheValPheAsn
GlyThrSerTrpPhe IleThrGlnArgAsn PhePheSerProGln IleIleThrThrAsp
AsnThrPheValSer GlyAsnCysAspVal ValIleGlyIleIle AsnAsnThrValTyr
AspProLeuGlnPro GluLeuAspSerPhe LysGluGluLeuAsp LysTyrPheLysAsn
HisThrSerProAsp ValAspLeuGlyAsp IleSerGlyIleAsn AlaSerValValAsn
IleGlnLysGluIle AspArgLeuAsnGlu ValAlaLysAsnLeu AsnGluSerLeuIle
AspLeuGlnGluLeu GlyLysTyrGluGln TyrIleLysTrpPro TrpTyrValTrpLeu
GlyPheIleAlaGly LeuIleAlaIleVal MetValThrIleLeu LeuCysCysMetThr
SerCysCysSerCys LeuLysGlyAlaCys SerCysGlySerCys CysLysPheAspGlu
AspAspSerGluPro ValLeuLysGly ValLysLeuHisTyr Thr
所述的SARS冠状病毒N蛋白的氨基酸序列为:
MetSerAspAsnGly ProGlnSerAsnGln ArgSerAlaProArg IleThrPheGlyGly
ProThrAspSerThr AspAsnAsnGlnAsn GlyGlyArgAsnGly AlaArgProLysGln
ArgArgProGlnGly LeuProAsnAsnThr AlaSerTrpPheThr AlaLeuThrGlnHis
GlyLysGluGluLeu ArgPheProArgGly GlnGlyValProIle AsnThrAsnSerGly
ProAspAspGlnIle GlyTyrTyrArgArg AlaThrArgArgVal ArgGlyGlyAspGly
LysMetLysGluLeu SerProArgTrpTyr PheTyrTyrLeuGly ThrGlyProGluAla
SerLeuProTyrGly AlaAsnLysGluGly IleValTrpValAla ThrGluGlyAlaLeu
AsnThrProLysAsp HisIleGlyThrArgAsn ProAsnAsnAsnAla AlaThrValLeuGln
LeuProGlnGlyThr ThrLeuProLysGly PheTyrAlaGluGly SerArgGlyGlySer
GlnAlaSerSerArg SerSerSerArgSer ArgGlyAsnSerArg AsnSerThrProGly
SerSerArgGlyAsn SerProAlaArgMet AlaSerGlyGlyGly GluThrAlaLeuAla
LeuLeuLeuLeuAsp ArgLeuAsnGlnLeu GluSerLysValSer GlyLysGlyGlnGln
GlnGlnGlyGlnThr ValThrLysLysSer AlaAlaGluAlaSer LysLysProArgGln
LysArgThrAlaThr LysGlnTyrAsnVal ThrGlnAlaPheGly ArgArgGlyProGlu
GlnThrGlnGlyAsn PheGlyAspGlnAsp LeuIleArgGlnGly ThrAspTyrLysHis
TrpProGlnIleAla GlnPheAlaProSer AlaSerAlaPhePhe GlyMetSerArgIle
GlyMetGluValThr ProSerGlyThrTrp LeuThrTyrHisGly AlaIleLysLeuAsp
AspLysAspProGln PheLysAspAsnVal IleLeuLeuAsnLys HisIleAspAlaTyr
LysThrPheProPro ThrGluProLysLys AspLysLysLysLys ThrAspGluAlaGln
ProLeuProGlnArg GlnLysLysGlnPro ThrValThrLeuLeu ProAlaAlaAspMet
AspAspPheSerArg GlnLeuGlnAsnSer MetSerGlyAlaSer AlaAspSerThrGln Ala
所述的SARS冠状病毒M蛋白的氨基酸序列为:
MetAlaAspAsnGly ThrIleThrValGlu GluLeuLysGlnLeu LeuGluGlnTrpAsn
LeuValIleGlyPhe LeuPheLeuAlaTrp IleMetLeuLeuGln PheAlaTyrSerAsn
ArgAsnArgPheLeu TyrIleIleLysLeu ValPheLeuTrpLeu LeuTrpProValThr
LeuAlaCysPheVal LeuAlaAlaValTyr ArgIleAsnTrpVal ThrGlyGlyIleAla
IleAlaMetAlaCys IleValGlyLeuMet TrpLeuSerTyrPhe ValAlaSerPheArg
LeuPheAlaArgThr ArgSerMetTrpSer PheAsnProGluThr AsnIleLeuLeuAsn
ValProLeuArgGly ThrIleValThrArg ProLeuMetGluSer GluLeuValIleGly
AlaValIleIleArg GlyHisLeuArgMet AlaGlyHisSerLeu GlyArgCysAspIle
LysAspLeuProLys GluIleThrValAla ThrSerArgThrLeu SerTyrTyrLysLeu
GlyAlaSerGlnArg ValGlyThrAspSer GlyPheAlaAlaTyr AsnArgTyrArgIle
GlyAsnTyrLysLeu AsnThrAspHisAla GlySerAsnAspAsn IleAlaLeuLeuVal Gln
所述的SARS冠状病毒E蛋白的氨基酸序列为:
MetTyrSerPheVal SerGluGluThrGly ThrLeuIleValAsn SerValLeuLeuPhe
LeuAlaPheValVal PheLeuLeuValThr LeuAlaIleLeuThr AlaLeuArgLeuCys
AlaTyrCysCysAsn IleValAsnValSer LeuValLysProThr ValTyrValTyrSer
ArgValLysAsnLeu AsnSerSerGluGly ValProAspLeuLeu Val
将此用于检测SARS抗体的免疫微球依次分别用1%BSA、5%甘油、0.01%NaN3、0.01M的pH8.0的PBS缓冲液重悬,并用400w超声波处理20秒,备用。
本发明提供一种所述的用于检测SARS抗体的免疫微球的用途。该免疫微球可以作为检测试剂检测抗(SARS)抗体,其检测方法如下:
将被测血清样品滴在洁净的玻片或透明塑料片上,加入本发明提供的用于检测SARS抗体的免疫微球,其中,偶联了作为抗原的SARS冠状病毒S,N,M或E蛋白的免疫微球各占1/4,用竹签、牙签、塑料棒或其他物体搅拌,将待测样品和免疫微球混匀并呈圆斑状。
在黑色背景下,用肉眼或在显微镜下直接观察凝集反应,并用下列符号记录结果:
(-)无肉眼可见凝集颗粒;
(+)肉眼可见细的凝集颗粒,背景混浊;
(++)肉眼可见大的凝集颗粒,背景稍混浊;
(+++)肉眼可见大而清晰凝集颗粒,背景清楚;
(++++)肉眼可见大而清晰的凝集块,背景清楚。
也可进行半定量测定抗体滴度,将被测血清倍比稀释,按上法测定,以稀释度为抗体滴度。
SARS病是一种严重的传染性极强的烈性传染病,需要快速、准确地进行诊断。本发明提供的用于检测SARS(严重急性呼吸综合症)抗体的免疫微球是将基因重组的SARS冠状病毒S,N,M,E蛋白通过化学方法偶联到(乳胶)聚苯乙烯微球上。该免疫微球与现有技术相比,其有益效果为:
第一,准确性高。因为使用的基因工程重组抗原,其纯度达到99%,为此,避免了PCR诊断试剂盒的假阳性的缺点;
第二,快速。整个检测过程仅需要数分钟,避免了酶联免疫诊断试剂盒需要数小时的费时的缺点;
第三,经济实用。检测不需要任何仪器设备,适合广大基层卫生防疫单位使用。
总之,该免疫微球能够快速检测血清抗SARS抗体,且敏感性和特异性均好。
附图说明
图1为免疫微球检测SARS抗体:左(阴性),右(阳性);
图2为免疫前、后兔血清与SARS CoV的基因重组蛋白免疫微球反应(40X);其中:A.免疫前兔血清;B.免疫后兔血清;
图3为正常人和病人血清与SARS CoV基因重组蛋白免疫微球反应;其中:A.正常人血清(10X);B.SARS病人血清(强反应(10X);C.SARS病人血清(强反应40X);D.SARS病人血清(1∶200稀释40X)。
具体实施方式
实施例1、偶联了作为抗原的SARS冠状病毒S蛋白的免疫微球的制备
SARS冠状病毒S蛋白抗原的制备及鉴定:
制备——用基因重组技术克隆、表达和纯化SARS冠状病毒S蛋白作为抗原:用RT-PCR方法扩增SARS冠状病毒S的基因片段,将该基因片段经测序证实基因序列正确无误后,再将其克隆到表达载体如原核表达载体pQE30,或酵母表达载体pPICZαA,然后进行表达和蛋白纯化。
鉴定——抗原纯化后,通过以下试验进行鉴定:
1)抗原蛋白含量测定:取抗原1毫升用分光光度计测其蛋白含量,在其260nm和280nm处分别测OD值后,用公式280nm Odx1.45-260nmODx0.74即可计算抗原的蛋白含量1mg/ml左右;
2)抗原蛋白纯度测定:取抗原20微升(含蛋白量5微克)走蛋白电泳即SDS-PAGE电泳,结果显示为一条带。
3)酶联免疫试验(ELISA):以2.5微克/毫升抗原200微升包被酶标微孔板,置4℃20小时后,弃去抗原包被液,加入5%小牛血清以封闭未被抗原包被的部分,置37℃1小时,经PBS-吐温和PBS缓冲液洗涤后,加阳性病人血清,置37℃2小时,经PBS-吐温和PBS缓冲液洗涤后加入最适工作浓度HRP标记的羊抗人IgG 200微升,置室温2小时后,分别用PBS-吐温和PBS缓冲液洗涤各3次,加入反应底物200微升,再495nm测定吸光度。
4)对照实验:用免疫微球10微升加入10微升抗体阳性血清和阴性血清,混匀后,阳性血清有凝集颗粒,阴性血清则无凝集。
免疫微球的制备:
1)将直径为200纳米的聚苯乙烯微球15mg/ml,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时,以12000转/分离心10分钟,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
2)向步骤1)得到的混合液中加入0.1mg/ml的多聚赖氨酸,置室温上下摇动12小时,用0.5M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时;用0.5M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
3)向步骤2)得到的混合液中加入作为抗原的SARS冠状病毒S蛋白0.2mg/ml,置室温上下摇动12小时,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.1M的pH8.8的碳酸盐缓冲液;加入50微升0.25M乙酰胺封闭多聚赖氨酸上未被抗原结合的羧基部分,加入乙酰胺后,置室温上下摇动30分,以13000转/分离心10分钟,分出固体;
4)重悬于1g/ml牛血清(BSA)和0.015M的pH 7.5的碳酸盐缓冲液,置室温上下摇动30分,离心分出固体,得到用于检测SARS抗体的、偶联了作为抗原的SARS冠状病毒S蛋白的免疫微球。
将此用于检测SARS抗体的免疫微球依次分别用1%BSA、5%甘油、0.01%NaN3、0.01M的pH8.0的PBS缓冲液重悬,并用400w超声波处理20秒,备用。
实施例2、偶联了作为抗原的SARS冠状病毒N蛋白的免疫微球的制备
SARS冠状病毒N蛋白抗原的制备及鉴定:
制备——用基因重组技术克隆、表达和纯化SARS冠状病毒N蛋白作为抗原:用RT-PCR方法扩增SARS冠状病毒N的基因片段,将该基因片段经测序证实基因序列正确无误后,再将其克隆到表达载体如原核表达载体pQE30,或酵母表达载体pPICZαA,然后进行表达和蛋白纯化。
鉴定——抗原纯化后,通过以下试验进行鉴定:
1)抗原蛋白含量测定:取抗原1毫升用分光光度计测其蛋白含量,在其260nm和280nm处分别测OD值后,用公式280nm Odx1.45-260nmODx0.74即可计算抗原的蛋白含量1mg/ml左右;
2)抗原蛋白纯度测定:取抗原20微升(含蛋白量5微克)走蛋白电泳即SDS-PAGE电泳,结果显示为一条带。
3)酶联免疫试验(ELISA):以2.5微克/毫升抗原200微升包被酶标微孔板,置4℃20小时后,弃去抗原包被液,加入5%小牛血清以封闭未被抗原包被的部分,置37℃1小时,经PBS-吐温和PBS缓冲液洗涤后,加阳性病人血清,置37℃2小时,经PBS-吐温和PBS缓冲液洗涤后加入最适工作浓度HRP标记的羊抗人IgG 200微升,置室温2小时后,分别用PBS-吐温和PBS缓冲液洗涤各3次,加入反应底物200微升,再495nm测定吸光度。
4)对照实验:用免疫微球10微升加入10微升抗体阳性血清和阴性血清,混匀后,阳性血清有凝集颗粒,阴性血清则无凝集。
免疫微球的制备:
1)将直径为200纳米的聚苯乙烯微球15mg/ml,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时,以12000转/分离心10分钟,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
2)向步骤1)得到的混合液中加入0.1mg/ml的多聚赖氨酸,置室温上下摇动12小时,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时;用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
3)向步骤2)得到的混合液中加入作为抗原的SARS冠状病毒N蛋白0.2mg/ml,置室温上下摇动12小时,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.1M的pH8.8的碳酸盐缓冲液;加入50微升0.25M乙酰胺封闭多聚赖氨酸上未被抗原结合的羧基部分,加入乙酰胺后,置室温上下摇动30分,以13000转/分离心10分钟,分出固体;
4)重悬于1g/ml牛血清(BSA)和0.015M的pH 7.5的碳酸盐缓冲液,置室温上下摇动30分,离心分出固体,得到用于检测SARS抗体的、偶联了作为抗原的SARS冠状病毒N蛋白的免疫微球。
将此用于检测SARS抗体的免疫微球依次分别用1%BSA、5%甘油、0.01%NaN3、0.01M的pH8.0的PBS缓冲液重悬,并用400w超声波处理20秒,备用。
实施例3、偶联了作为抗原的SARS冠状病毒M蛋白的免疫微球的制备
SARS冠状病毒M蛋白抗原的制备及鉴定:
制备——用基因重组技术克隆、表达和纯化SARS冠状病毒M蛋白作为抗原:用RT-PCR方法扩增SARS冠状病毒M的基因片段,将该基因片段经测序证实基因序列正确无误后,再将其克隆到表达载体如原核表达载体pQE30,或酵母表达载体pPICZαA,然后进行表达和蛋白纯化。
鉴定——抗原纯化后,通过以下试验进行鉴定:
1)抗原蛋白含量测定:取抗原1毫升用分光光度计测其蛋白含量,在其260nm和280nm处分别测OD值后,用公式280nm Odx1.45-260nmODx0.74即可计算抗原的蛋白含量1mg/ml左右:
2)抗原蛋白纯度测定:取抗原20微升(含蛋白量5微克)走蛋白电泳即SDS-PAGE电泳,结果显示为一条带。
3)酶联免疫试验(ELISA):以2.5微克/毫升抗原200微升包被酶标微孔板,置4℃20小时后,弃去抗原包被液,加入5%小牛血清以封闭未被抗原包被的部分,置37℃1小时,经PBS-吐温和PBS缓冲液洗涤后,加阳性病人血清,置37℃2小时,经PBS-吐温和PBS缓冲液洗涤后加入最适工作浓度HRP标记的羊抗人IgG 200微升,置室温2小时后,分别用PBS-吐温和PBS缓冲液洗涤各3次,加入反应底物200微升,再495nm测定吸光度。
4)对照实验:用免疫微球10微升加入10微升抗体阳性血清和阴性血清,混匀后,阳性血清有凝集颗粒,阴性血清则无凝集。
免疫微球的制备:
1)将直径为200纳米的聚苯乙烯微球15mg/ml,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时,以12000转/分离心10分钟,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
2)向步骤1)得到的混合液中加入0.1mg/ml的多聚赖氨酸,置室温上下摇动12小时,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时;用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
3)向步骤2)得到的混合液中加入作为抗原的SARS冠状病毒M蛋白0.2mg/ml,置室温上下摇动12小时,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.1M的pH8.8的碳酸盐缓冲液;加入50微升0.25M乙酰胺封闭多聚赖氨酸上未被抗原结合的羧基部分,加入乙酰胺后,置室温上下摇动30分,以13000转/分离心10分钟,分出固体;
4)重悬于1g/ml牛血清(BSA)和0.015M的pH 7.5的碳酸盐缓冲液,置室温上下摇动30分,离心分出固体,得到用于检测SARS抗体的、偶联了作为抗原的SARS冠状病毒M蛋白的免疫微球。
将此用于检测SARS抗体的免疫微球依次分别用1%BSA、5%甘油、0.01%NaN3、0.01M的pH8.0的PBS缓冲液重悬,并用400w超声波处理20秒,备用。
实施例4、偶联了作为抗原的SARS冠状病毒E蛋白的免疫微球的制备
SARS冠状病毒E蛋白抗原的制备及鉴定:
制备——用基因重组技术克隆、表达和纯化SARS冠状病毒E蛋白作为抗原:用RT-PCR方法扩增SARS冠状病毒E的基因片段,将该基因片段经测序证实基因序列正确无误后,再将其克隆到表达载体如原核表达载体pQE30,或酵母表达载体pPICZαA,然后进行表达和蛋白纯化。
鉴定——抗原纯化后,通过以下试验进行鉴定:
1)抗原蛋白含量测定:取抗原1毫升用分光光度计测其蛋白含量,在其260nm和280nm处分别测OD值后,用公式280nm Odx1.45-260nmODx0.74即可计算抗原的蛋白含量1mg/ml左右;
2)抗原蛋白纯度测定:取抗原20微升(含蛋白量5微克)走蛋白电泳即SDS-PAGE电泳,结果显示为一条带。
3)酶联免疫试验(ELISA):以2.5微克/毫升抗原200微升包被酶标微孔板,置4℃20小时后,弃去抗原包被液,加入5%小牛血清以封闭未被抗原包被的部分,置37℃1小时,经PBS-吐温和PBS缓冲液洗涤后,加阳性病人血清,置37℃2小时,经PBS-吐温和PBS缓冲液洗涤后加入最适工作浓度HRP标记的羊抗人IgG 200微升,置室温2小时后,分别用PBS-吐温和PBS缓冲液洗涤各3次,加入反应底物200微升,再495nm测定吸光度。
4)对照实验:用免疫微球10微升加入10微升抗体阳性血清和阴性血清,混匀后,阳性血清有凝集颗粒,阴性血清则无凝集。
免疫微球的制备:
1)将直径为200纳米的聚苯乙烯微球15mg/ml,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时,以12000转/分离心10分钟,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
2)向步骤1)得到的混合液中加入0.1mg/ml的多聚赖氨酸,置室温上下摇动12小时,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH4的磷酸缓冲液,然后加入0.2mg/ml的碳二亚胺,置室温上下摇动4小时;用0.1M的pH8.8的碳酸盐缓冲液洗涤3次,重悬于0.01M的pH 7.5的碳酸盐缓冲液;
3)向步骤2)得到的混合液中加入作为抗原的SARS冠状病毒E蛋白0.2mg/ml,置室温上下摇动12小时,用0.1M的pH8.8的碳酸盐缓冲液洗涤3次后,重悬于0.1M的pH8.8的碳酸盐缓冲液;加入50微升0.25M乙酰胺封闭多聚赖氨酸上未被抗原结合的羧基部分,加入乙酰胺后,置室温上下摇动30分,以13000转/分离心10分钟,分出固体;
4)重悬于1g/ml牛血清(BSA)和0.015M的pH 7.5的碳酸盐缓冲液,置室温上下摇动30分,离心分出固体,得到用于检测SARS抗体的、偶联了作为抗原的SARS冠状病毒E蛋白的免疫微球。
将此用于检测SARS抗体的免疫微球依次分别用1%BSA、5%甘油、0.01%NaN3、0.01M的pH8.0的PBS缓冲液重悬,并用400w超声波处理20秒,备用。
实施例5、用本发明提供的免疫微球检测试剂检测抗(SARS)抗体
实验方法:
将被测血清样品10微升滴在洁净的玻片或透明塑料片上,加入5微升本发明提供的用于检测SARS抗体的免疫微球,其中,实施例1~4制备的偶联了作为抗原的SARS冠状病毒S,N,M或E蛋白的免疫微球各占1/4,用竹签、牙签、塑料棒或其他物体搅拌,将待测样品和免疫微球混匀并呈直径1厘米的圆斑状。
在黑色背景下,用肉眼或在显微镜下直接观察凝集反应,并用下列符号记录结果:
(-)无肉眼可见凝集颗粒;
(+)肉眼可见细的凝集颗粒,背景混浊;
(++)肉眼可见大的凝集颗粒,背景稍混浊;
(+++)肉眼可见大而清晰凝集颗粒,背景清楚;
(++++)肉眼可见大而清晰的凝集块,背景清楚。
实验样品:
1)正常兔血清和分别免疫SARS病毒的S、N、M、E蛋白兔血清;
2)正常人血清和SARS患者血清;
实验结果:
如图2所示,在40倍显微镜下观察,正常的兔血清与免疫微球呈阴性反应,可见均匀的微球颗粒;感染了SARS病毒的兔血清与免疫微球呈阳性反应,可见微球颗粒凝集呈块。
如图3所示,在10倍显微镜下观察,正常人的血清与免疫微球(SARS CoV基因重组蛋白免疫微球是偶联了SARS-S蛋白)呈阴性反应,可见均匀的微球颗粒;SARS病人的血清与免疫微球呈阳性反应,可见微球颗粒凝集呈块。
对SARS患者样品进行半定量测定抗体滴度,将被测血清倍比稀释,按上法测定,以稀释度为抗体滴度。观察结果见图3,其中,稀释度为200倍时,仍为阳性(如图1右图),稀释度为1∶200时,呈阳性(如图1左图),因此,该1∶200样品的抗体滴度(即稀释度)为1∶20。
SEQUENCE LISTING
<110>中国科学院动物研究所
<120>一种用于检测SARS抗体的免疫微球及其制备方法和用途
<130>FPI04040
<150>CN 200410003420.1
<151>2004-02-25
<160>4
<170>PatentIn version 3.1
<210>1
<211>1255
<212>PRT
<213>corona virus
<400>1
Met Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr Ser Gly Ser Asp Leu
1 5 10 15
Asp Arg Cys Thr Thr Phe Asp Asp Val Gln Ala Pro Asn Tyr Thr Gln
20 25 30
His Thr Ser Ser Met Arg Gly Val Tyr Tyr Pro Asp Glu Ile Phe Arg
35 40 45
Ser Asp Thr Leu Tyr Leu Thr Gln Asp Leu Phe Leu Pro Phe Tyr Ser
50 55 60
Asn Val Thr Gly Phe His Thr Ile Asn His Thr Phe Asp Asn Pro Val
65 70 75 80
Ile Pro Phe Lys Asp Gly Ile Tyr Phe Ala Ala Thr Glu Lys Ser Asn
85 90 95
Val Val Arg Gly Trp Val Phe Gly Ser Thr Met Asn Asn Lys Ser Gln
100 105 110
Ser Val Ile Ile Ile Asn Asn Ser Thr Asn Val Val Ile Arg Ala Cys
115 120 125
Asn Phe Glu Leu Cys Asp Asn Pro Phe Phe Ala Val Ser Lys Pro Met
130 135 140
Gly Thr Gln Thr His Thr Met Ile Phe Asp Asn Ala Phe Asn Cys Thr
145 150 155 160
Phe Glu Tyr Ile Ser Asp Ala Phe Ser Leu Asp Val Ser Glu Lys Ser
165 170 175
Gly Asn Phe Lys His Leu Arg Glu Phe Val Phe Lys Asn Lys Asp Gly
180 185 190
Phe Leu Tyr Val Tyr Lys Gly Tyr Gln Pro Ile Asp Val Val Arg Asp
195 200 205
Leu Pro Ser Gly Phe Asn Thr Leu Lys Pro Ile Phe Lys Leu Pro Leu
210 215 220
Gly Ile Asn Ile Thr Asn Phe Arg Ala Ile Leu Thr Ala Phe Ser Pro
225 230 235 240
Ala Gln Asp Thr Trp Gly Thr Ser Ala Ala Ala Tyr Phe Val Gly Tyr
245 250 255
Leu Lys Pro Thr Thr Phe Met Leu Lys Tyr Asp Glu Asn Gly Thr Ile
260 265 270
Thr Asp Ala Val Asp Cys Ser Gln Asn Pro Leu Ala Glu Leu Lys Cys
275 280 285
Ser Val Lys Ser Phe Glu Ile Asp Lys Gly Ile Tyr Gln Thr Ser Asn
290 295 300
Phe Arg Val Val Pro Ser Gly Asp Val Val Arg Phe Pro Asn Ile Thr
305 310 315 320
Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Lys Phe Pro Ser
325 330 335
Val Tyr Ala Trp Glu Arg Lys Lys Ile Ser Asn Cys Val Ala Asp Tyr
340 345 350
Ser Val Leu Tyr Asn Ser Thr Phe Phe Ser Thr Phe Lys Cys Tyr Gly
355 360 365
Val Ser Ala Thr Lys Leu Asn Asp Leu Cys Phe Ser Asn Val Tyr Ala
370 375 380
Asp Ser Phe Val Val Lys Gly Asp Asp Val Arg Gln Ile Ala Pro Gly
385 390 395 400
Gln Thr Gly Val Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe
405 410 415
Met Gly Cys Val Leu Ala Trp Asn Thr Arg Asn Ile Asp Ala Thr Ser
420 425 430
Thr Gly Asn Tyr Asn Tyr Lys Tyr Arg Tyr Leu Arg His Gly Lys Leu
435 440 445
Arg Pro Phe Glu Arg Asp Ile Ser Asn Val Pro Phe Ser Pro Asp Gly
450 455 460
Lys Pro Cys Thr Pro Pro Ala Leu Asn Cys Tyr Trp Pro Leu Asn Asp
465 470 475 480
Tyr Gly Phe Tyr Thr Thr Thr Gly Ile Gly Tyr Gln Pro Tyr Arg Val
485 490 495
Val Val Leu Ser Phe Glu Leu Leu Asn Ala Pro Ala Thr Val Cys Gly
500 505 510
Pro Lys Leu Ser Thr Asp Leu Ile Lys Asn Gln Cys Val Asn Phe Asn
515 520 525
Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Pro Ser Ser Lys Arg
530 535 540
Phe Gln Pro Phe Gln Gln Phe Gly Arg Asp Val Ser Asp Phe Thr Asp
545 550 555 560
Ser Val Arg Asp Pro Lys Thr Ser Glu Ile Leu Asp Ile Ser Pro Cys
565 570 575
Ser Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Ala Ser Ser
580 585 590
Glu Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Asp Val Ser Thr
595 600 605
Ala Ile His Ala Asp Gln Leu Thr Pro Ala Trp Arg Ile Tyr Ser Thr
610 615 620
Gly Asn Asn Val Phe Gln Thr Gln Ala Gly Cys Leu Ile Gly Ala Glu
625 630 635 640
His Val Asp Thr Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile
645 650 655
Cys Ala Ser Tyr His Thr Val Ser Leu Leu Arg Ser Thr Ser Gln Lys
660 665 670
Ser Ile Val Ala Tyr Thr Met Ser Leu Gly Ala Asp Ser Ser Ile Ala
675 680 685
Tyr Ser Asn Asn Thr Ile Ala Ile Pro Thr Asn Phe Ser Ile Ser Ile
690 695 700
Thr Thr Glu Val Met Pro Val Ser Met Ala Lys Thr Ser Val Asp Cys
705 710 715 720
Asn Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ala Asn Leu Leu Leu
725 730 735
Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Ser Gly Ile
740 745 750
Ala Ala Glu Gln Asp Arg Asn Thr Arg Glu Val Phe Ala Gln Val Lys
755 760 765
Gln Met Tyr Lys Thr Pro Thr Leu Lys Tyr Phe Gly Gly Phe Asn Phe
770 775 780
Ser Gln Ile Leu Pro Asp Pro Leu Lys Pro Thr Lys Arg Ser Phe Ile
785 790 795 800
Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Met
805 810 815
Lys Gln Tyr Gly Glu Cys Leu Gly Asp Ile Asn Ala Arg Asp Leu Ile
820 825 830
Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr
835 840 845
Asp Asp Met Ile Ala Ala Tyr Thr Ala Ala Leu Val Ser Gly Thr Ala
850 855 860
Thr Ala Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile Pro Phe
865 870 875 880
Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn
885 890 895
Val Leu Tyr Glu Asn Gln Lys Gln Ile Ala Asn Gln Phe Asn Lys Ala
900 905 910
Ile Ser Gln Ile Gln Glu Ser Leu Thr Thr Thr Ser Thr Ala Leu Gly
915 920 925
Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu
930 935 940
Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn
945 950 955 960
Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp
965 970 975
Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln
980 985 990
Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala
995 1000 1005
Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys Arg Val Asp
1010 1015 1020
Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro Gln Ala Ala
1025 1030 1035
Pro His Gly Val Val Phe Leu His Val Thr Tyr Val Pro Ser Gln
1040 1045 1050
Glu Arg Asn Phe Thr Thr Ala Pro Ala Ile Cys His Glu Gly Lys
1055 1060 1065
Ala Tyr Phe Pro Arg Glu Gly Val Phe Val Phe Asn Gly Thr Ser
1070 1075 1080
Trp Phe Ile Thr Gln Arg Asn Phe Phe Ser Pro Gln Ile Ile Thr
1085 1090 1095
Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val Val Ile Gly
1100 1105 1110
Ile Ile Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro Glu Leu Asp
1115 1120 1125
Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn His Thr Ser
1130 1135 1140
Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val
1145 1150 1155
Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala Lys
1160 1165 1170
Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr
1175 1180 1185
Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Val Trp Leu Gly Phe Ile
1190 1195 1200
Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile Leu Leu Cys Cys
1205 1210 1215
Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Ala Cys Ser Cys Gly
1220 1225 1230
Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys
1235 1240 1245
Gly Val Lys Leu His Tyr Thr
1250 1255
<210>2
<211>422
<212>PRT
<213>corona virus
<400>2
Met Ser Asp Asn Gly Pro Gln Ser Asn Gln Arg Ser Ala Pro Arg Ile
1 5 10 15
Thr Phe Gly Gly Pro Thr Asp Ser Thr Asp Asn Asn Gln Asn Gly Gly
20 25 30
Arg Asn Gly Ala Arg Pro Lys Gln Arg Arg Pro Gln Gly Leu Pro Asn
35 40 45
Asn Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His Gly Lys Glu Glu
50 55 60
Leu Arg Phe Pro Arg Gly Gln Gly Val Pro Ile Asn Thr Asn Ser Gly
65 70 75 80
Pro Asp Asp Gln Ile Gly Tyr Tyr Arg Arg Ala Thr Arg Arg Val Arg
85 90 95
Gly Gly Asp Gly Lys Met Lys Glu Leu Ser Pro Arg Trp Tyr Phe Tyr
100 105 110
Tyr Leu Gly Thr Gly Pro Glu Ala Ser Leu Pro Tyr Gly Ala Asn Lys
115 120 125
Glu Gly Ile Val Trp Val Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys
130 135 140
Asp His Ile Gly Thr Arg Asn Pro Asn Asn Asn Ala Ala Thr Val Leu
145 150 155 160
Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly
165 170 175
Ser Arg Gly Gly Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg Ser Arg
180 185 190
Gly Asn Ser Arg Asn Ser Thr Pro Gly Ser Ser Arg Gly Asn Ser Pro
195 200 205
Ala Arg Met Ala Ser Gly Gly Gly Glu Thr Ala Leu Ala Leu Leu Leu
210 215 220
Leu Asp Arg Leu Asn Gln Leu Glu Ser Lys Val Ser Gly Lys Gly Gln
225 230 235 240
Gln Gln Gln Gly Gln Thr Val Thr Lys Lys Ser Ala Ala Glu Ala Ser
245 250 255
Lys Lys Pro Arg Gln Lys Arg Thr Ala Thr Lys Gln Tyr Asn Val Thr
260 265 270
Gln Ala Phe Gly Arg Arg Gly Pro Glu Gln Thr Gln Gly Asn Phe Gly
275 280 285
Asp Gln Asp Leu Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln
290 295 300
lle Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg
305 310 315 320
Ile Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr His Gly
325 330 335
Ala Ile Lys Leu Asp Asp Lys Asp Pro Gln Phe Lys Asp Asn Val Ile
340 345 350
Leu Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu
355 360 365
Pro Lys Lys Asp Lys Lys Lys Lys Thr Asp Glu Ala Gln Pro Leu Pro
370 375 380
Gln Arg Gln Lys Lys Gln Pro Thr Val Thr Leu Leu Pro Ala Ala Asp
385 390 395 400
Met Asp Asp Phe Ser Arg Gln Leu Gln Asn Ser Met Ser Gly Ala Ser
405 410 415
Ala Asp Ser Thr Gln Ala
420
<210>3
<211>221
<212>PRT
<213>corona virus
<400>3
Met Ala Asp Asn Gly Thr Ile Thr Val Glu Glu Leu Lys Gln Leu Leu
1 5 10 15
Glu Gln Trp Asn Leu Val Ile Gly Phe Leu Phe Leu Ala Trp Ile Met
20 25 30
Leu Leu Gln Phe Ala Tyr Ser Asn Arg Asn Arg Phe Leu Tyr Ile Ile
35 40 45
Lys Leu Val Phe Leu Trp Leu Leu Trp Pro Val Thr Leu Ala Cys Phe
50 55 60
Val Leu Ala Ala Val Tyr Arg Ile Asn Trp Val Thr Gly Gly Ile Ala
65 70 75 80
Ile Ala Met Ala Cys Ile Val Gly Leu Met Trp Leu Ser Tyr Phe Val
85 90 95
Ala Ser Phe Arg Leu Phe Ala Arg Thr Arg Ser Met Trp Ser Phe Asn
100 105 110
Pro Glu Thr Asn Ile Leu Leu Asn Val Pro Leu Arg Gly Thr Ile Val
115 120 125
Thr Arg Pro Leu Met Glu Ser Glu Leu Val Ile Gly Ala Val Ile Ile
130 135 140
Arg Gly His Leu Arg Met Ala Gly His Ser Leu Gly Arg Cys Asp Ile
145 150 155 160
Lys Asp Leu Pro Lys Glu I le Thr ValAla Thr Ser Arg Thr Leu Ser
165 170 175
Tyr Tyr Lys Leu Gly Ala Ser Gln Arg Val Gly Thr Asp Ser Gly Phe
180 185 190
Ala Ala Tyr Asn Arg Tyr Arg Ile Gly Asn Tyr Lys Leu Asn Thr Asp
195 200 205
His Ala Gly Ser Asn Asp Asn Ile Ala Leu Leu Val Gln
210 215 220
<210>4
<211>76
<212>PRT
<213>corona virus
<400>4
Met Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser
1 5 10 15
Val Leu Leu Phe Leu Ala Phe Val Val Phe Leu Leu Val Thr Leu Ala
20 25 30
Ile Leu Thr Ala Leu Arg Leu Cys Ala Tyr Cys Cys Asn Ile Val Asn
35 40 45
Val Ser Leu Val Lys Pro Thr Val Tyr Val Tyr Ser Arg Val Lys Asn
50 55 60
Leu Asn Ser Ser Glu Gly Val Pro Asp Leu Leu Val
65 70 75
Claims (2)
1、 一种用于检测SARS抗体的免疫微球,其为以聚苯乙烯微球为内核,其表面的羧基通过多聚赖氨酸偶联了作为抗原的SARS冠状病毒S,N,M或E蛋白,所述的聚苯乙烯微球为表面直径为200~900纳米,其表面有羧基修饰;
所述的SARS冠状病毒S蛋白的氨基酸序列为:
MetPheIlePheLeu LeuPheLeuThrLeu ThrSerGlySerAsp LeuAspArgCysThr
ThrPheAspAspVal GlnAlaProAsnTyr ThrGlnHisThrSer SerMetArgGlyVal
TyrTyrProAspGlu IlePheArgSerAsp ThrLeuTyrLeuThr GlnAspLeuPheLeu
ProPheTyrSerAsn ValThrGlyPheHis ThrIleAsnHisThr PheAspAsnProVal
IleProPheLysAsp GlyIleTyrPheAla AlaThrGluLysSer AsnValValArgGly
TrpValPheGlySer ThrMetAsnAsnLys SerGlnSerValIle IleIleAsnAsnSer
ThrAsnValValIle ArgAlaCysAsnPhe GluLeuCysAspAsn ProPhePheAlaVal
SerLysProMetGly ThrGlnThrHisThr MetIlePheAspAsn AlaPheAsnCysThr
PheGluTyrIleSer AspAlaPheSerLeu AspValSerGluLys SerGlyAsnPheLys
HisLeuArgGluPhe ValPheLysAsnLys AspGlyPheLeuTyr ValTyrLysGlyTyr
GlnProI leAspVal ValArgAspLeuPro SerGlyPheAsnThr LeuLysProIlePhe
LysLeuProLeuGly IleAsnIleThrAsn PheArgAlaIleLeu ThrAlaPheSerPro
AlaGlnAspThrTrp GlyThrSerAlaAla AlaTyrPheValGly TyrLeuLysProThr
ThrPheMetLeuLys TyrAspGluAsnGly ThrIleThrAspAla ValAspCysSerGln
AsnProLeuAlaGlu LeuLysCysSerVal LysSerPheGluIle AspLysGlyIleTyr
GlnThrSerAsnPhe ArgValValProSer GlyAspValValArg PheProAsnIleThr
AsnLeuCysProPhe GlyGluValPheAsn AlaThrLysPhePro SerValTyrAlaTrp
GluArgLysLysIle SerAsnCysValAla AspTyrSerValLeu TyrAsnSerThrPhe
PheSerThrPheLys CysTyrGlyValSer AlaThrLysLeuAsn AspLeuCysPheSer
AsnValTyrAlaAsp SerPheValValLys GlyAspAspValArg GlnIleAlaProGly
GlnThrGlyValIle AlaAspTyrAsnTyr LysLeuProAspAsp PheMetGlyCysVal
LeuAlaTrpAsnThr ArgAsnIleAspAla ThrSerThrGlyAsn TyrAsnTyrLysTyr
ArgTyrLeuArgHis GlyLysLeuArgPro PheGluArgAspIle SerAsnValProPhe
SerProAspGlyLys ProCysThrProPro AlaLeuAsnCysTyr TrpProLeuAsnAsp
TyrGlyPheTyrThr ThrThrGlyIleGly TyrGlnProTyrArg ValValValLeuSer
PheGluLeuLeuAsn AlaProAlaThrVal CysGlyProLysLeu SerThrAspLeuIle
LysAsnGlnCysVal AsnPheAsnPheAsn GlyLeuThrGlyThr GlyValLeuThrPro
SerSerLysArgPhe GlnProPheGlnGln PheGlyArgAspVal SerAspPheThrAsp
SerValArgAspPro LysThrSerGluIle LeuAspIleSerPro CysSerPheGlyGly
ValSerValIleThr ProGlyThrAsnAla SerSerGluValAla ValLeuTyrGlnAsp
ValAsnCysThrAsp ValSerThrAlaIle HisAlaAspGlnLeu ThrProAlaTrpArg
IleTyrSerThrGly AsnAsnValPheGln ThrGlnAlaGlyCys LeuIleGlyAlaGlu
HisValAspThrSer TyrGluCysAspIle ProIleGlyAlaGly IleCysAlaSerTyr
HisThrValSerLeu LeuArgSerThrSer GlnLysSerIleVal AlaTyrThrMetSer
LeuGlyAlaAspSer SerIleAlaTyrSer AsnAsnThrIleAla IleProThrAsnPhe
SerIleSerIleThr ThrGluValMetPro ValSerMetAlaLys ThrSerValAspCys
AsnMetTyrIleCys GlyAspSerThrGlu CysAlaAsnLeuLeu LeuGlnTyrGlySer
PheCysThrGlnLeu AsnArgAlaLeuSer GlyIleAlaAlaGlu GlnAspArgAsnThr
ArgGluValPheAla GlnValLysGlnMet TyrLysThrProThr LeuLysTyrPheGly
GlyPheAsnPheSer GlnIleLeuProAsp ProLeuLysProThr LysArgSerPheIle
GluAspLeuLeuPhe AsnLysValThrLeu AlaAspAlaGlyPhe MetLysGlnTyrGly
GluCysLeuGlyAsp IleAsnAlaArgAsp LeuIleCysAlaGln LysPheAsnGlyLeu
ThrValLeuProPro LeuLeuThrAspAsp MetIleAlaAlaTyr ThrAlaAlaLeuVal
SerGlyThrAlaThr AlaGlyTrpThrPhe GlyAlaGlyAlaAla LeuGlnIleProPhe
AlaMetGlnMetAla TyrArgPheAsnGly IleGlyValThrGln AsnValLeuTyrGlu
AsnGlnLysGlnIle AlaAsnGlnPheAsn LysAlaIleSerGln IleGlnGluSerLeu
ThrThrThrSerThr AlaLeuGlyLysLeu GlnAspValValAsn GlnAsnAlaGlnAla
LeuAsnThrLeuVal LysGlnLeuSerSer AsnPheGlyAlaIle SerSerValLeuAsn
AspIleLeuSerArg LeuAspLysValGlu AlaGluValGlnIle AspArgLeuIleThr
GlyArgLeuGlnSer LeuGlnThrTyrVal ThrGlnGlnLeuIle ArgAlaAlaGluIle
ArgAlaSerAlaAsn LeuAlaAlaThrLys MetSerGluCysVal LeuGlyGlnSerLys
ArgValAspPheCys GlyLysGlyTyrHis LeuMetSerPhePro GlnAlaAlaProHis
GlyValValPheLeu HisValThrTyrVal ProSerGlnGluArg AsnPheThrThrAla
ProAlaIleCysHis GluGlyLysAlaTyr PheProArgGluGly ValPheValPheAsn
GlyThrSerTrpPhe IleThrGlnArgAsn PhePheSerProGln IleIleThrThrAsp
AsnThrPheValSer GlyAsnCysAspVal ValIleGlyIleIle AsnAsnThrValTyr
AspProLeuGlnPro GluLeuAspSerPhe LysGluGluLeuAsp LysTyrPheLysAsn
HisThrSerProAsp ValAspLeuGlyAsp IleSerGlyIleAsn AlaSerValValAsn
IleGlnLysGluIle AspArgLeuAsnGlu ValAlaLysAsnLeu AsnGluSerLeuIle
AspLeuGlnGluLeu GlyLysTyrGluGln TyrIleLysTrpPro TrpTyrValTrpLeu
GlyPheIleAlaGly LeuIleAlaIleVal MetValThrIleLeu LeuCysCysMetThr
SerCysCysSerCys LeuLysGlyAlaCys SerCysGlySerCys CysLysPheAspGlu
AspAspSerGluPro ValLeuLysGly ValLysLeuHisTyr Thr
所述的SARS冠状病毒N蛋白的氨基酸序列为:
MetSerAspAsnGly ProGlnSerAsnGln ArgSerAlaProArg IleThrPheGlyGly
ProThrAspSerThr AspAsnAsnGlnAsn GlyGlyArgAsnGly AlaArgProLysGln
ArgArgProGlnGly LeuProAsnAsnThr AlaSerTrpPheThr AlaLeuThrGlnHis
GlyLysGluGluLeu ArgPheProArgGly GlnGlyValProIle AsnThrAsnSerGly
ProAspAspGlnIle GlyTyrTyrArgArg AlaThrArgArgVal ArgGlyGlyAspGly
LysMetLysGluLeu SerProArgTrpTyr PheTyrTyrLeuGly ThrGlyProGluAla
SerLeuProTyrGly AlaAsnLysGluGly IleValTrpValAla ThrGluGlyAlaLeu
AsnThrProLysAsp HisIleGlyThrArgAsn ProAsnAsnAsnAla AlaThrValLeuGln
LeuProGlnGlyThr ThrLeuProLysGly PheTyrAlaGluGly SerArgGlyGlySer
GlnAlaSerSerArg SerSerSerArgSer ArgGlyAsnSerArg AsnSerThrProGly
SerSerArgGlyAsn SerProAlaArgMet AlaSerGlyGlyGly GluThrAlaLeuAla
LeuLeuLeuLeuAsp ArgLeuAsnGlnLeu GluSerLysValSer GlyLysGlyGlnGln
GlnGlnGlyGlnThr ValThrLysLysSer AlaAlaGluAlaSer LysLysProArgGln
LysArgThrAlaThr LysGlnTyrAsnVal ThrGlnAlaPheGly ArgArgGlyProGlu
GlnThrGlnGlyAsn PheGlyAspGlnAsp LeuIleArgGlnGly ThrAspTyrLysHis
TrpProGlnIleAla GlnPheAlaProSer AlaSerAlaPhePhe GlyMetSerArgIle
GlyMetGluValThr ProSerGlyThrTrp LeuThrTyrHisGly AlaIleLysLeuAsp
AspLysAspProGln PheLysAspAsnVal IleLeuLeuAsnLys HisIleAspAlaTyr
LysThrPheProPro ThrGluProLysLys AspLysLysLysLys ThrAspGluAlaGln
ProLeuProGlnArg GlnLysLysGlnPro ThrValThrLeuLeu ProAlaAlaAspMet
AspAspPheSerArg GlnLeuGlnAsnSer MetSerGlyAlaSer AlaAspSerThrGln Ala
所述的SARS冠状病毒M蛋白的氨基酸序列为:
MetAlaAspAsnGly ThrIleThrValGlu GluLeuLysGlnLeu LeuGluGlnTrpAsn
LeuValIleGlyPhe LeuPheLeuAlaTrp IleMetLeuLeuGln PheAlaTyrSerAsn
ArgAsnArgPheLeu TyrIleIleLysLeu ValPheLeuTrpLeu LeuTrpProValThr
LeuAlaCysPheVal LeuAlaAlaValTyr ArgIleAsnTrpVal ThrGlyGlyIleAla
IleAlaMetAlaCys IleValGlyLeuMet TrpLeuSerTyrPhe ValAlaSerPheArg
LeuPheAlaArgThr ArgSerMetTrpSer PheAsnProGluThr AsnIleLeuLeuAsn
ValProLeuArgGly ThrIleValThrArg ProLeuMetGluSer GluLeuValIleGly
AlaValIleIleArg GlyHisLeuArgMet AlaGlyHisSerLeu GlyArgCysAspIle
LysAspLeuProLys GluIleThrValAla ThrSerArgThrLeu SerTyrTyrLysLeu
GlyAlaSerGlnArg ValGlyThrAspSer GlyPheAlaAlaTyr AsnArgTyrArgIle
GlyAsnTyrLysLeu AsnThrAspHisAla GlySerAsnAspAsn IleAlaLeuLeuVal Gln
所述的SARS冠状病毒E蛋白的氨基酸序列为:
MetTyrSerPheVal SerGluGluThrGly ThrLeuIleValAsn SerValLeuLeuPhe
LeuAlaPheValVal PheLeuLeuValThr LeuAlaIleLeuThr AlaLeuArgLeuCys
AlaTyrCysCysAsn IleValAsnValSer LeuValLysProThr ValTyrValTyrSer
ArgValLysAsnLeu AsnSerSerGluGly ValProAspLeuLeu Val。
2、 一种权利要求1所述的用于检测SARS抗体的免疫微球的制备方法,是采用化学偶联法将SARS冠状病毒S,N,M或E蛋白作为抗原偶联到微球,包括如下的步骤:
1)将聚苯乙烯微球15~20mg/ml,用0.1~0.5M的pH8,8~9.8的碳酸盐缓冲液洗涤后,重悬于0.01~0.05M的pH4~5的磷酸缓冲液,然后加入2~4mg/ml的碳二亚胺,于室温反应完全后,离心,用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤,重悬于0.01~0.05M的pH 7.5~8.5的碳酸盐缓冲液;所述的聚苯乙烯微球直径为200~900纳米,其表面有羧基修饰;
2)向步骤1)得到的混合液中加入0.2~2.4mg/ml的多聚赖氨酸,于室温反应完全;用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤后,重悬于0.01~0.05M的pH4~5的磷酸缓冲液,然后加入2~4mg/ml的碳二亚胺,于室温反应完全;用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤,重悬于0.01~0.05M的pH 7.5~8.5的碳酸盐缓冲液;
3)向步骤2)得到的混合液中加入作为抗原的SARS冠状病毒S,N,M或E蛋白0.2~2.4mg/ml,于室温反应完全;用0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液洗涤后,重悬于0.1~0.5M的pH8.8~9.8的碳酸盐缓冲液;加入50~200微升0.25M乙酰胺,于室温反应完全后,离心分出固体;
4)重悬于1g/ml牛血清(BSA)和0.01~0.05M的pH 7.5~8.5的碳酸盐缓冲液,于室温反应完全后,离心分出固体,得到用于检测SARS抗体的免疫微球。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100701474A CN100425991C (zh) | 2004-02-25 | 2004-08-03 | 一种用于检测sars抗体的免疫微球及其制备方法和用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410003420.1 | 2004-02-25 | ||
CN200410003420 | 2004-02-25 | ||
CNB2004100701474A CN100425991C (zh) | 2004-02-25 | 2004-08-03 | 一种用于检测sars抗体的免疫微球及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1661372A CN1661372A (zh) | 2005-08-31 |
CN100425991C true CN100425991C (zh) | 2008-10-15 |
Family
ID=35010807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100701474A Expired - Fee Related CN100425991C (zh) | 2004-02-25 | 2004-08-03 | 一种用于检测sars抗体的免疫微球及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100425991C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6234817B2 (ja) * | 2010-09-23 | 2017-11-22 | バイオセプト, インコーポレイテッド | シグナル増幅のための方法と試薬 |
CN105255992B (zh) * | 2015-10-15 | 2019-04-05 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 隐孢子虫和贾第鞭毛虫检测及质控试剂盒 |
CN113317572A (zh) * | 2020-02-28 | 2021-08-31 | 中国科学院化学研究所 | 用于呼出气冠状病毒的可视化快速检测口罩及其制备方法 |
WO2021179418A1 (en) * | 2020-03-09 | 2021-09-16 | Tsinghua University | Detection of immune response to sars-cov-2 |
CN111551713A (zh) * | 2020-05-15 | 2020-08-18 | 中国科学院过程工程研究所 | 一种covid-19病毒抗体检测微球及其制备方法和含该微球的试剂盒 |
CN113740538A (zh) * | 2020-05-27 | 2021-12-03 | 复旦大学 | 一种检测SARS-CoV-2新型冠状病毒IgM/IgG抗体的方法和产品 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378084A (zh) * | 2002-04-19 | 2002-11-06 | 王滔 | 测定粪便样品中幽门螺杆菌的免疫微球方法 |
US20030087548A1 (en) * | 2001-11-07 | 2003-05-08 | Sumitomo Wiring Systems, Ltd. | Connector and method for assembling a connector |
CN1445549A (zh) * | 2003-05-09 | 2003-10-01 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种检测sars病毒抗体的试剂盒,其制备方法及用途 |
CN1453590A (zh) * | 2003-06-18 | 2003-11-05 | 广州万孚生物技术有限公司 | SARS冠状病毒抗体IgG免疫印迹诊断试剂盒 |
CN1469126A (zh) * | 2003-04-26 | 2004-01-21 | 杭州华大基因研发中心 | 检测sars冠状病毒抗体的方法及其试剂盒 |
US20040018564A1 (en) * | 2002-07-29 | 2004-01-29 | Jsr Corporation | Physiologically active substance-measuring reagent and method for measuring physiologically active substance |
-
2004
- 2004-08-03 CN CNB2004100701474A patent/CN100425991C/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030087548A1 (en) * | 2001-11-07 | 2003-05-08 | Sumitomo Wiring Systems, Ltd. | Connector and method for assembling a connector |
CN1378084A (zh) * | 2002-04-19 | 2002-11-06 | 王滔 | 测定粪便样品中幽门螺杆菌的免疫微球方法 |
US20040018564A1 (en) * | 2002-07-29 | 2004-01-29 | Jsr Corporation | Physiologically active substance-measuring reagent and method for measuring physiologically active substance |
CN1469126A (zh) * | 2003-04-26 | 2004-01-21 | 杭州华大基因研发中心 | 检测sars冠状病毒抗体的方法及其试剂盒 |
CN1445549A (zh) * | 2003-05-09 | 2003-10-01 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种检测sars病毒抗体的试剂盒,其制备方法及用途 |
CN1453590A (zh) * | 2003-06-18 | 2003-11-05 | 广州万孚生物技术有限公司 | SARS冠状病毒抗体IgG免疫印迹诊断试剂盒 |
Non-Patent Citations (2)
Title |
---|
纳米磁性微粒合成制备方法及在酶联免疫吸附试验中德初步应用. 任翊等.中华微生物学和免疫学杂志,第23卷第3期. 2003 * |
酶联免疫吸附反应德技术进展及应用. 李文敏.湖北职业技术学院学报,第6卷第4期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1661372A (zh) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111217920B (zh) | 新冠病毒n-s优势表位融合蛋白、制备方法、应用,及表达蛋白、微生物、应用,试剂盒 | |
CN111072774B (zh) | 抗非洲猪瘟p30蛋白单域抗体和检测非洲猪瘟病毒的elisa试剂盒 | |
JP2012185165A (ja) | 組み合わせc型肝炎ウイルス抗原及び抗体検出法 | |
CN104101706A (zh) | 一种检测甲流抗原的胶体金免疫层析试纸条及检测甲流抗原的方法 | |
CN106279378B (zh) | 水痘带状疱疹病毒gE抗原及其在检测抗水痘带状疱疹病毒抗体中的用途 | |
CN101661044A (zh) | 一种结核病诊断试剂及试剂盒 | |
EP1328811B1 (en) | Hcv mosaic antigen composition | |
CN100425991C (zh) | 一种用于检测sars抗体的免疫微球及其制备方法和用途 | |
Malipiero et al. | Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 | |
CN113321715B (zh) | 新型冠状病毒抗原及其检测用途 | |
EP1745291A1 (en) | Detection of west nile virus | |
CN102449483A (zh) | 对生物学样品中的sith-1抗体进行检测的方法 | |
CN100504391C (zh) | 用于检测sars抗原的免疫微球及其制备方法 | |
CN111929445B (zh) | 新型冠状病毒抗体的检测试剂 | |
CN109342724A (zh) | 一种检测肺炎支原体的试剂盒 | |
Calidonio et al. | Biophysical and biochemical insights in the design of immunoassays | |
JP2011069800A (ja) | ヒトインフルエンザウイルスh1亜型の免疫学的鑑別検出法 | |
Takacs et al. | Detection and characterization of antibodies to PEG-IFN-alpha2b using surface plasmon resonance | |
WO2021205228A1 (en) | Assay device | |
CN103149357B (zh) | 一种利用竞争法检测牛布鲁氏菌抗体的检测试纸卡 | |
CN102590505A (zh) | 抗肠道病毒71型衣壳蛋白1 IgM AlphaLISA检测试剂盒 | |
Zhang et al. | Development of a dot-immunoenzyme filtration assay for the detection of enterovirus 71 antigen in human serum via immunoglobulin M | |
Richalet-Sécordel et al. | Uses of biosensor technology in the development of probes for viral diagnosis | |
CN103149356B (zh) | 一种利用夹心法检测牛布鲁氏菌抗原的检测试纸卡 | |
WO2022129443A1 (en) | Lateral flow tests |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081015 Termination date: 20110803 |